Bintrafusp alfa works by targeting PD-L1 through IgG, and the peptide chain ends are fused with the extracellular domain of two TGF-β receptor II molecules, designed to “capture TGF-β” in the tumor microenvironment. Here, CD274 is linked to neoplasm.